XHR7XGA
Replacement Skin, Left Lower Extremity to New Technology Group 10 with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | H Skin, Subcutaneous Tissue, Fascia and Breast |
| Operation | R Replacement |
| Body Part | 7 Skin, Left Lower Extremity |
| Approach | X External |
| Device | G Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy |
| Qualifier | A New Technology Group 10 |
Operation Definition
Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part
Procedure Overview
This family covers using an advanced synthetic or biological material to physically take the place of skin, subcutaneous tissue, fascia, or breast tissue that has been removed or damaged, most commonly seen in breast reconstruction after mastectomy or in complex wound and soft tissue reconstruction. Instead of relying solely on a patient's own tissue flap or a standard implant, the surgeon uses an engineered tissue substitute, such as an advanced acellular matrix, to rebuild the physical structure and contour of the area. This approach can reduce the need for additional donor-site surgery and may support better integration with the patient's own tissue over time as the scaffold is gradually incorporated by the body. It is generally offered as an option within a broader reconstructive plan, discussed alongside the more traditional flap or implant choices, with the tradeoffs of material cost, healing pattern, and long-term durability weighed against those alternatives.
Anatomy & Axis Detail
Skin, Left Lower Extremity
Skin of the left lower extremity shares the same vulnerability to poor perfusion and chronic wound formation as the right leg and foot, particularly below the knee where venous and arterial disease commonly limit healing. Replacement with a skin substitute is used when a chronic ulcer, traumatic wound, or post-debridement defect has a wound bed unlikely to support a conventional graft, offering a scaffold that encourages the patient's own tissue to grow in before or in place of grafting. Because ambulation and weight-bearing depend on durable skin over the foot and ankle, the choice of substitute and the staging of treatment often account for how soon the patient needs to bear weight again. As with the right leg, the precise level of involvement and laterality must be recorded clearly to distinguish this procedure from contralateral or more proximal treatment.
Approach: External
External approach in New Technology applies to procedures performed directly on the skin, mucous membranes, or via direct visualization without penetrating a body cavity, such as applying or activating a device against the body surface. It contrasts with Percutaneous approaches, which require instrument entry through the skin rather than surface-level contact.
Device / Substance / Technology: Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy
This value identifies prademagene zamikeracel, a genetically engineered autologous cell therapy in which a patient's own skin cells are gene-corrected in the laboratory and then applied to chronic wounds, most notably in recessive dystrophic epidermolysis bullosa. It is distinguished from allogeneic bioengineered constructs by using the patient's own modified cells rather than donor-derived tissue. The therapy aims to promote durable wound closure by restoring functional skin protein production.
Qualifier: New Technology Group 10
New Technology Group 10 flags a procedure as part of the 2023 batch of add-on codes recognized under the New Technology section. The value itself carries no information about the device or drug involved; that comes from the table, body part, and approach values alongside it. Coders should not confuse it with Group 9 or Group 11, which cover the cohorts approved in the years immediately before and after.
Coding & Documentation
Assignment depends on documentation identifying the specific new-technology material used and confirming that it physically replaced tissue rather than simply reinforcing what remained, since Replacement and Supplement are distinguished by whether structure was fully substituted versus augmented. The operative note should describe the extent of tissue removed and the material placed to take its structural role. A common error is coding a standard Replacement from the Medical and Surgical section instead of the New Technology equivalent because the specific product name was omitted from the note, or conflating this with a Supplement code when the material was actually layered onto existing tissue rather than replacing removed tissue.
Commonly Confused With
The key point of confusion is with Supplement procedures in the same body system, where material reinforces or augments tissue that is still present rather than replacing tissue that was removed; if any native structure remains and is simply being bolstered, Supplement applies instead. It is also distinguished from autologous flap reconstruction, which uses the patient's own tissue and is coded under different root operations entirely, and from standard implant-based breast reconstruction, which may not qualify for a New Technology code unless the specific advanced material used is documented.